353 related articles for article (PubMed ID: 17075599)
1. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor.
Winthrop KL
Nat Clin Pract Rheumatol; 2006 Nov; 2(11):602-10. PubMed ID: 17075599
[TBL] [Abstract][Full Text] [Related]
2. Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy.
Strangfeld A; Listing J
Best Pract Res Clin Rheumatol; 2006 Dec; 20(6):1181-95. PubMed ID: 17127203
[TBL] [Abstract][Full Text] [Related]
3. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2004 Aug; 53(30):683-6. PubMed ID: 15295313
[TBL] [Abstract][Full Text] [Related]
4. [Infectious risk].
Calabuig E; Salavert M
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
[TBL] [Abstract][Full Text] [Related]
5. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.
Salmon-Ceron D; Tubach F; Lortholary O; Chosidow O; Bretagne S; Nicolas N; Cuillerier E; Fautrel B; Michelet C; Morel J; Puéchal X; Wendling D; Lemann M; Ravaud P; Mariette X;
Ann Rheum Dis; 2011 Apr; 70(4):616-23. PubMed ID: 21177290
[TBL] [Abstract][Full Text] [Related]
6. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease.
Theis VS; Rhodes JM
Aliment Pharmacol Ther; 2008 Jan; 27(1):19-30. PubMed ID: 17944997
[TBL] [Abstract][Full Text] [Related]
7. Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections.
Moiton MP; Richez C; Dumoulin C; Mehsen N; Dehais J; Schaeverbeke T
Clin Microbiol Infect; 2006 Dec; 12(12):1151-3. PubMed ID: 17121619
[TBL] [Abstract][Full Text] [Related]
8. Infections associated with tumor necrosis factor-alpha antagonists.
Rychly DJ; DiPiro JT
Pharmacotherapy; 2005 Sep; 25(9):1181-92. PubMed ID: 16164393
[TBL] [Abstract][Full Text] [Related]
9. Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments.
Bieber J; Kavanaugh A
Rheum Dis Clin North Am; 2004 May; 30(2):257-70, v. PubMed ID: 15172039
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
11. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.
Leombruno JP; Einarson TR; Keystone EC
Ann Rheum Dis; 2009 Jul; 68(7):1136-45. PubMed ID: 18753157
[TBL] [Abstract][Full Text] [Related]
12. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.
Wolfe F; Michaud K
Arthritis Rheum; 2007 May; 56(5):1433-9. PubMed ID: 17469100
[TBL] [Abstract][Full Text] [Related]
13. [Increased risk of infection with biological immunomodifying antirheumatic agents. Clear guidelines are necessary as shown by case reports].
Söderlin M; Blomkvist C; Dahl P; Forsberg P; Fohlman J
Lakartidningen; 2005 Dec 5-11; 102(49):3794-6, 3799-800. PubMed ID: 16408703
[TBL] [Abstract][Full Text] [Related]
14. [Tuberculosis associated with anti-TNF therapy].
Takeno M; Murakami S; Ishigatsubo Y
Nihon Rinsho; 2007 Jul; 65(7):1308-13. PubMed ID: 17642248
[TBL] [Abstract][Full Text] [Related]
15. [Tuberculosis among patients treated with TNF-alpha blockers].
Fuchs-Polychuck I; Avnon LS; Abu-Shakra M
Harefuah; 2007 Mar; 146(3):212-8, 245. PubMed ID: 17460930
[TBL] [Abstract][Full Text] [Related]
16. The risk of infections with biologic therapies for rheumatoid arthritis.
Furst DE
Semin Arthritis Rheum; 2010 Apr; 39(5):327-46. PubMed ID: 19117595
[TBL] [Abstract][Full Text] [Related]
17. Serious infections associated with anticytokine therapies in the rheumatic diseases.
Giles JT; Bathon JM
J Intensive Care Med; 2004; 19(6):320-34. PubMed ID: 15523118
[TBL] [Abstract][Full Text] [Related]
18. Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor {alpha}.
Winthrop KL
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv29-30. PubMed ID: 16239382
[No Abstract] [Full Text] [Related]
19. [Infectious risks of immunomodulating therapies in rheumatology].
Van Delden C
Rev Med Suisse; 2006 Mar; 2(57):738-40, 743-5. PubMed ID: 16604876
[TBL] [Abstract][Full Text] [Related]
20. [Recommendations for the diagnosis and treatment of latent and active tuberculosis in patients with inflammatory joint diseases treated with tumour necrosis factor alpha inhibitors].
Fonseca JE; Lucas H; Canhão H; Duarte R; Santos MJ; Villar M; Faustino A; Raymundo E; ;
Acta Reumatol Port; 2006; 31(3):237-45. PubMed ID: 17094335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
